Prostate Cancer Diagnostics Market Segmentation:
Test Type (Diagnostics Tests, Imaging Tests)
The diagnostic tests segment is poised to capture around 65% prostate cancer diagnostics market share by the end of 2035 due to innovation in biomarker tests and mounting emphasis on early diagnosis. Diagnostic tests allow for accurate and less invasive detection of prostate cancer, thus addressing the growing need for accessible prostate cancer screening. In July 2023, Quest Diagnostics introduced AmeriPath's biomarker test for prostate cancer, underlining the dependency on diagnostic tests for early detection. Such product launches indicate the growth prospects of the segment during the forecast period.
Cancer Type (Prostatic Adenocarcinoma, Small Cell Carcinoma, Other Prostate Cancer Types)
By the end of 2035, prostatic adenocarcinoma segment is estimated to account for more than 76% prostate cancer diagnostics market share, as it is among the most prevalent types of prostate cancer. Since prostatic adenocarcinoma has a high incidence worldwide, the demand for diagnostic tools specifically meant for tracking and diagnosis of these types of cancers increases. In August 2023, Myriad Genetics introduced Absolute Risk Reduction for the Prolaris Prostate Cancer Prognostic Test, aimed at helping patients with prostatic adenocarcinoma make more informed decisions regarding their treatment options. This approach by companies to offer diagnostics in prostatic adenocarcinoma offers continued growth in the market.
Our in-depth analysis of the prostate cancer diagnostics market includes the following segments:
|
Test Type |
|
|
Cancer Type |
|
|
End use |
|
